Monoamine oxidase inhibitors (MAOIs) have well-established efficacy for treating depression, panic disorder, and social phobia.
In addition, in order to evaluate suspected alterations in the monoaminergic system, we investigated behavioral responses to tranylcypromine (Tcy), a
monoamine oxidase inhibitor.
The antidepressants, mood lifting drugs, fall into three main groups: the tricyclics, the "atypical" (or second generation) group, and the
monoamine oxidase inhibitors (MAOI).
Treatment of tricyclic refractory depression with a
monoamine oxidase inhibitor antidepressant.
In a survey of psychiatrists with AIDS expertise, the top choices for first-line treatment of depression in patients with HIV who had not yet started antiretrovirals were desipramine, amitriptyline, fluvoxamine, or a
monoamine oxidase inhibitor, Dr.
The agent is a selective
monoamine oxidase inhibitor (MAOI).
ZUTRIPRO([TM]) Oral Solution is contraindicated in individuals with hypersensitivity to hydrocodone, pseudoephedrine HCl, chlorpheniramine, or any of the inactive ingredients; individuals receiving
monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy; and individuals with narrow angle glaucoma, urinary retention, severe hypertension or severe coronary artery disease.
The recent approval of an irreversible
monoamine oxidase inhibitor for treating Parkinson's disease includes an indication for patients with early disease as well as for those with more advanced disease who are already on levodopa.
The major Parkinson's disease growth driver over the 2005-09 period was the dopamine agonist class, which accounted for nearly half the Parkinson's disease market sales, supported by the continued uptake of the newer catechol-O-methyltransferase (COMT) inhibitor and
monoamine oxidase inhibitor (MAOI) classes.
It should not be prescribed for patients with arteriosclerosis, symptomatic heart disease, moderate to severe hypertension, hyperthyroidism, seizures, glaucoma, agitated states, a history of substance abuse problems, a known allergy or unusual reactions to sympathomimetic amines, or for patients who have taken a
monoamine oxidase inhibitor in the previous 14 days.
The Food and Drug Administration's approval of a transdermal patch containing selegiline, an irreversible
monoamine oxidase inhibitor, for treating major depression could bring much-needed help to the large population of patients that has not responded to uptake inhibitors.
Transdermal selegiline may make it possible to achieve the antidepressant efficacy of a
monoamine oxidase inhibitor without the dietary restrictions and acute hypertensive risks that have been largely responsible for the fall from favor of this drug class, Dr.